RBC Capital Maintains Outperform on Edgewise Therapeutics, Maintains $32 Price Target
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Leonid Timashev has reiterated an 'Outperform' rating for Edgewise Therapeutics (NASDAQ:EWTX) and maintained a price target of $32.
September 17, 2024 | 6:57 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital has reiterated its 'Outperform' rating for Edgewise Therapeutics, maintaining a price target of $32. This suggests confidence in the company's future performance.
The reaffirmation of an 'Outperform' rating and a $32 price target by RBC Capital indicates a positive outlook for Edgewise Therapeutics. This can lead to increased investor confidence and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100